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Abstract
Background: During the first two decades of the U.S. AIDS epidemic, and unlike some malignancies, breast cancer risk was
significantly lower for women with human immunodeficiency virus (HIV) infection compared to the general population. This
deficit in HIV-associated breast cancer could not be attributed to differences in survival, immune deficiency, childbearing or
other breast cancer risk factors. HIV infects mononuclear immune cells by binding to the CD4 molecule and to CCR5 or
CXCR4 chemokine coreceptors. Neoplastic breast cells commonly express CXCR4 but not CCR5. In vitro, binding HIV
envelope protein to CXCR4 has been shown to induce apoptosis of neoplastic breast cells. Based on these observations, we
hypothesized that breast cancer risk would be lower among women with CXCR4-tropic HIV infection.
Methods and Findings: We conducted a breast cancer nested case-control study among women who participated in the
WIHS and HERS HIV cohort studies with longitudinally collected risk factor data and plasma. Cases were HIV-infected women
(mean age 46 years) who had stored plasma collected within 24 months of breast cancer diagnosis and an HIV viral load
$500 copies/mL. Three HIV-infected control women, without breast cancer, were matched to each case based on age and
plasma collection date. CXCR4-tropism was determined by a phenotypic tropism assay. Odds ratios (OR) and 95%
confidence intervals (CI) for breast cancer were estimated by exact conditional logistic regression. Two (9%) of 23 breast
cancer cases had CXCR4-tropic HIV, compared to 19 (28%) of 69 matched controls. Breast cancer risk was significantly and
independently reduced with CXCR4 tropism (adjusted odds ratio, 0.10, 95% CI 0.002–0.84) and with menopause (adjusted
odds ratio, 0.08, 95% CI 0.001–0.83). Adjustment for CD4
+ cell count, HIV viral load, and use of antiretroviral therapy did not
attenuate the association between infection with CXCR4-tropic HIV and breast cancer.
Conclusions: Low breast cancer risk with HIV is specifically linked to CXCR4-using variants of HIV. These variants are thought
to exclusively bind to and signal through a receptor that is commonly expressed on hyperplastic and neoplastic breast duct
cells. Additional studies are needed to confirm these observations and to understand how CXCR4 might reduce breast
cancer risk.
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Introduction
Human immunodeficiency virus type-1 (HIV) envelope protein
binds to the CD4 receptor and to chemokine coreceptors CCR5 or
CXCR4, leading to infection and destruction of the CD4-bearing
immune cells: T lymphocytes and macrophages [1]. Although HIV
infection increases the risk of several malignancies,[2] from 1980–
2002 breast cancer risk in the United States was 31% lower among
women with AIDS compared to the general population [3]. This
cancer deficit was unrelated to crude measures of immune
deficiency, was most pronounced before 1990, and gradually
disappeared with improving antiretroviral therapy (ART) [3].
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immune cells, but also on hyperplastic and especially on malignant
breast duct cells [4–6]. CXCR4 may play an essential role in
metastasis and, indirectly, earlier stages of tumor growth [4,5,7–9].
Linking HIV with breast cancer was the observation that
programmed cell death (apoptosis) was induced in human breast
cancer cell lines through binding of CXCR4-tropic, but not
CCR5-tropic, HIV envelope protein [10]. Based on both the
pattern of breast cancer risk in women with AIDS and the in vitro
findings that CXCR4-tropic HIV induced apoptosis of breast
cancer cells, we postulated that HIV strains tropic for CXCR4
may account for the reduction in breast cancer observed in HIV-
infected women. To test this hypothesis, we studied HIV tropism
in women with breast cancer and in matched controls.
Methods
Cohorts, Covariate Data and Specimens, and Ethics
Statement
The study population was drawn from two large multisite
longitudinal studies of HIV infection in women in the United
States, the Women’s Interagency HIV Study (WIHS) and the HIV
Epidemiology Research Study (HERS). Study protocols were
reviewed and approved by the institutional review boards, and
written informed consent was obtained from the participants.
The WIHS is a prospective study of HIV infection in women,
conducted in New York City, Washington D.C., Chicago,
Southern California and the San Francisco Bay Area. The WIHS
methods and baseline cohort characteristics have been previously
described [11]. Briefly, between October 1994 and November
1995, 2056 HIV-infected and 569 uninfected women were
enrolled. A second enrollment between October 2001 and
September 2002, added 737 HIV-infected and 406 HIV-
uninfected women [12]. Follow-up of the women enrolled in the
WIHS is ongoing.
The HERS was a collaborative, multicenter (Baltimore, MD;
Bronx, NY; Providence, RI; and Detroit, MI) prospective study
that enrolled 871 HIV-seropositive and 439 HIV-seronegative
women with acknowledged HIV risk behavior from April 1993 to
January 1995. Women were enrolled on the basis of either
injection drug-use or sexual risk, as has been reported previously
[13]. Follow-up of the women enrolled in the HERS ended in
March 2000.
The WIHS and HERS protocols for core study visits and the
questionnaires used were, by design, extremely similar. At every
six month core visit, women participants were interviewed,
received a physical examination, and provided multiple gyneco-
logic and blood specimens. Among HIV-infected women, blood
samples collected at the core study visit were tested for CD4
+
lymphocytes and HIV RNA load.
Selection of Cases and Controls
Breast cancer cases were identified and confirmed through
medical records and state cancer registry matches, and date of
diagnosis determined. In the WIHS, cancers were identified from
January 1993 through June 2009 and in the HERS from April
1993 through March 2000. Cases for the current investigation
were HIV-infected women for whom we had stored plasma
samples that were within 24 months (either before or after) of their
cancer diagnosis and in which the HIV RNA viral load was 500
copies/mL or greater. A random sample program selected three
HIV-infected control women who did not have breast cancer, had
HIV RNA viral loads $500 copies/mL, and who matched to each
case based on cohort, age (plus or minus 2 years), and date of
plasma specimen collection (within six months).
HIV Tropism Determination
The primary independent variable was HIV coreceptor usage
(tropism), which was determined by the original Trofile assay
(Monogram Biosciences, South San Francisco CA. Figure S1).
Women were classified as having exclusively CCR5-tropic HIV
(‘‘R5’’) or as having CXCR4-tropic HIV (‘‘X4’’ or dual/mixed
tropism ‘‘R5/X4’’). The original Trofile assay has .99%
sensitivity to detect low levels of CXCR4 and CCR5 variants
that comprise at least 5–10% of a viral population, and the positive
and negative predictive value of the assay has been verified in
clinical trials of CCR5 antagonists [14].
Statistical Analyses
All analyses were pre-specified. Contingency table analyses were
conducted to compare the distribution of participant characteris-
tics by case-control status, and chi-square or Fisher exact tests
measured statistical significance. Paired t-tests were used to
measure equality of means for continuous variables. Unadjusted
and adjusted exact conditional, matched-pair, logistic regression
was performed. The following continuous variables were trans-
formed for the regression analyses: body mass index was divided
by 10, CD4
+ cell count was divided by 100, and HIV viral load
was the log10. Variables that were significant at the P-value ,0.10
level in the unadjusted regression models were included in the
adjusted analysis. Statistical analyses were performed using SASH
software version 9.2 [15].
Results
There were 29 confirmed breast cancer cases identified, 27 in
the WIHS and 2 in the HERS. Of 29 confirmed breast cancer
cases, three were excluded due to HIV viral load ,500 copies/
mL, and tropism results could not be determined in three others. A
total of 23 breast cancer cases, who had a mean age of 46 years,
were included in the analyses. Nearly all of these cancers were
invasive infiltrating ductal carcinoma, and they were distributed
across the years 1993–2009 (Table 1). Of 69 randomly selected
controls, tropism could not be determined in seven, who were
replaced with other cohort participants using the same random
selection program.
HIV Tropism in Cases and Controls
The characteristics of the 23 cases and 69 controls with HIV
tropism results are shown in Table S1. Only 2 (9%) breast cancer
cases had CXCR4-tropic HIV, compared to 19 (28%) of the
matched controls (Fisher’s exact P=0.09, Table S1). Two of the
seven replacement controls had CXCR4-tropic HIV, for a
prevalence of 29%, essentially the same as the originally selected
controls. Compared to participants with CCR5-tropic HIV, those
with CXCR4-tropic HIV had lower mean CD4
+ counts (213.5 vs
389.8 cells/uL, P=0.001) but similar mean HIV viral loads (4.4 vs
4.1 log10 copies/mL, P=0.21). In addition, tropism was not
associated with history of clinical AIDS or HIV viral load
(P=0.26).
Breast Cancer Risk by HIV Tropism and Other Variables
In unadjusted exact conditional regression analysis of 20
variables (Table S1), breast cancer was marginally inversely
associated with CXCR4-tropic HIV (Odds Ratio (OR)=0.20,
95% confidence interval (CI) 0.02–1.1) as well as menopause
(OR=0.13, 95% CI 0.003–1.0), defined as not having a menstrual
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any other variables (exact P-values all .0.1), including CD4
+ cell
count, HIV viral load, ART, race/ethnicity, and classical breast
cancer risk factors (Figure 1). In multivariable analysis, cancer risk
was reduced in women with CXCR4-tropic HIV (adjusted
OR=0.10, 95% CI 0.002–0.84) and with menopause (adjusted
OR=0.08, 95% CI 0.001–0.83). In additional multivariable
analyses, the adjusted OR and significance level for CXCR4-
tropic HIV was not attenuated by the inclusion of CD4
+ cell
count, use of ART, or HIV viral load in the regression models.
Discussion
These findings show that the odds of breast cancer in women
with CXCR4-tropic HIV were 90% lower than in women with
CCR5-tropic HIV. This is large enough to account for most of the
breast cancer deficit for women with AIDS in the United States
[3]. Our findings support the hypothesis that the low breast cancer
incidence observed in women with HIV/AIDS is specifically
linked to HIV variants that bind to CXCR4, a receptor that is
commonly expressed on hyperplastic and neoplastic breast cells.
This hypothesis was developed from three observations: 1) the
utilization of CXCR4 as the coreceptor for HIV X4 and R5/X4
strains [1], 2) the common and often high level expression of
CXCR4 in breast neoplasia [4–6], and 3) the induction of
apoptosis of breast cancer cells by the specific binding of CXCR4-
tropic HIV envelope to CXCR4 [10].
CXCR4 in Breast Neoplasia
Our data showing a reduced risk of breast cancer among
women with CXCR4-tropic HIV may reflect an effect of CXCR4
at an intermediate stage of breast neoplasia. Muller and colleagues
first observed that CXCR4 is commonly and often highly
expressed in primary breast cancers and in breast cancer cell
lines [5]. This observation has been replicated and extended by
many others, as reviewed by Luker and Luker [4]. Mammary stem
cells express CXCR4 mRNA, as well as many other genes [16],
although the relevance of this to breast neoplasia is speculative [4].
Notably, CXCR4 protein was observed by Schmid and colleagues
in 13 of 14 cases of ductal carcinoma in situ of the breast, as well as
in 13 of 14 areas of atypical ductal hyperplasia of the breast [6].
However, Schmid et al did not detect CXCR4 protein in normal
breast epithelium [6], consistent with scanty or absent mRNA
expression in cells derived from mammary epithelial tissue [5].
Overall, these data imply that normal epithelial breast cells would
have few targets for, and thus probably not be directly affected by,
CXCR4-tropic HIV envelope.
CXCR4 by Cell Type
The possibility that CXCR4-tropic HIV might inhibit tumor-
promoting macrophages [17] and that CXCR4 may differ
between mononuclear and breast cells should be considered.
CXCR4-tropic HIV envelope first binds to a CD4 epitope on T
lymphocytes or macrophages and then undergoes a conforma-
tional change that allows the virus to bind to surface CXCR4 and
enter the cell, causing death by various means including apoptosis
[1]. CXCR4-mediated apoptosis of uninfected bystander cells that
do not express CD4 has been reported, but this phenomenon
commonly involves a degree of interaction with CD4-bearing cells
[18]. In vitro experiments have reported that CD4-independent
interaction of CXCR4-tropic HIV mediates apoptosis of breast
cells, apparently requiring no CD4 expression or interaction to
mediate conformational change of HIV and occurring without
evidence of in vitro or ex vivo breast cell infection by HIV [10].
Conformational differences in the orientation or folding of surface
CXCR4 [19], including conformational differences between
immune versus breast cells [10], may be functionally important.
The additional possibility of HIV infection of breast cells should
also be considered [20].
Assessment of Potential Survivorship, Competing Risk,
and Screening Biases
Women with HIV infection may have other causes of morbidity
and mortality that prevent them from being diagnosed with breast
cancer or living long enough to develop breast cancer. With the
increasing availability and potency of ART, these competing
causes of morbidity and mortality are reduced, and thus HIV-
infected women are living longer and reaching the age of higher
breast cancer incidence. By matching the controls to the cases on
date of plasma collection we controlled for temporal trends in the
availability and potency of ART. We also matched the controls to
the age of the cases. CD4
+ cell counts were significantly lower in
our participants who had CXCR4-tropic HIV. This accords with
the well known tendency for patients infected with CXCR4-tropic
virus to have more rapid HIV disease progression compared to
those infected with only CCR5-tropic virus [1]. However,
CXCR4-tropic HIV was not significantly associated with HIV
viral load or history of clinical AIDS. Moreover, in multivariable
models that included CD4 cell count, use of ART, or HIV viral
load, the significance level for CXCR4-tropic HIV was not
attenuated. As a result, we have considered and minimized
competing risk as much as possible and still found a significant
association between CXCR4-tropic HIV and reduced risk of
breast cancer.
Screening bias may account for a fraction of the breast cancer
deficit. During ages 40–49, history of screening mammography
was reported by a smaller fraction of HIV-positive women in our
WIHS cohort (64%) compared to the general population
(79%).[21] Screening mammography history after age 50 was
nearly identical in the WIHS and general populations, although
the data were sparse.[21] Whether mammography screening is
related to HIV tropism is unknown.
Table 1. Histopathology and years of diagnosis of the 23
breast cancer cases in the WIHS and HERS cohort studies.
Tumor description* Total Number
Invasive infiltrating ductal carcinoma 16
Invasive infiltrating ductal and lobular carcinoma 2
Infiltrating ductal carcinoma in situ 2
Lobular carcinoma in situ 1
Adenocarcinoma 1
Not specified 1
Year of cancer diagnosis
1993–1996 6
1997–2000 3
2001–2004 9
2005–2008 4
2009 1
*Data obtained from medical records (pathology reports) and cancer registries
(histology and behavior).
doi:10.1371/journal.pone.0014349.t001
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Initial HIV infection with HIV subtype B is almost always
CCR5-tropic, with CXCR4-tropic virus emerging later, a shift
that may be retarded by highly active ART (HAART) [1]. We
postulate that gradual increases in HAART use and efficacy since
1996 may have been sufficient to account for the increasing trend
in breast cancer incidence [3]. In 2008, 71% of HIV-infected
women in the WIHS cohort were receiving HAART [N. Hessol,
unpublished data]. The observed 28% prevalence of CXCR4-
using HIV in our control group and 90% lower risk of breast
cancer associated with these HIV strains, would account for most
of the breast cancer deficit in women with AIDS [3,22].
Limitations and Contrary Data
We lacked ex vivo data to support the epidemiologic association
with CXCR4-tropic HIV. In addition to the reported induction of
apoptosis,[10] induction of various growth factors could contribute
to or account for the association.[7–9] Our study was very small
and limited to U.S. women who may not be representative of the
global HIV epidemic. In our evaluation of classical breast cancer
risk factors, we observed a lower risk associated with menopause.
This association is not surprising, especially in a population with a
mean age of 46 years, because early menopause is known to
decrease the risk of breast cancer [23]. Despite our hypothesis-
driven study that included many potential risk and confounding
factors, and our exclusion of survivorship and other potential
biases by matching and statistical adjustment, the association
between CXCR4-tropic virus and breast cancer may be spurious
due to an unmeasured viral or other exogenous or endogenous risk
factor.
It should be noted that during severe immune deficiency, when
CXCR4-tropic HIV is most prevalent, risks for Kaposi sarcoma
and central nervous system lymphoma are very high despite tumor
expression of CXCR4 [24,25]. Nevertheless, these particular
malignancies are distinct as they are known to be driven by herpes
virus transformation and thus may not utilize CXCR4 as a major
means of oncogenesis and metastasis. It is possible that our
observed association of CXCR4-tropic HIV is unique to breast
neoplasia due to conformational heterogeneity or variable surface
expression of CXCR4 epitopes on neoplastic breast duct cells
[10,19].
Summary and Implications
We found a 90% lower risk of breast cancer for women who
have circulating CXCR4-tropic HIV envelope, which points to
the possibility of a novel protective interaction between a specific
viral protein and cancer risk. The prototype selective antagonist of
CXCR4, AMD3100 (Plerixafor) [26], was reported to inhibit
apoptosis of breast cancer cells by CXCR4-tropic HIV [10], and
other inhibitors of CXCR4 are currently in development to treat
various cancers [27–29]. However, derivative studies should also
consider indirect pathways, such as blockade of pro-carcinogenic
effects of chemokines expressed by tumor-infiltrating macrophages
[17]. Continued studies of molecular interactions [8–10], of
patients with malignancies, and of populations at risk for these
diseases are needed to develop insight into the roles of CXCR4 in
breast and other cancers, which may lead to new approaches for
prevention or treatment.
Supporting Information
Table S1 Characteristics of the 23 breast cancer cases and 69
controls in the WIHS and HERS cohort studies. This table
provides the demographic characteristics, HIV-related parame-
ters, and breast cancer risk factor data, as well as univariate tests of
differences between cases and controls.
Found at: doi:10.1371/journal.pone.0014349.s001 (0.10 MB
DOC)
Figure S1 The Trofile Assay: RNA from patient plasma is
subjected to RT-PCR amplification to obtain a broad represen-
tation of envelope (env) genes from HIV populations. env
amplification products are then inserted into ‘‘HIV env expression
vectors’’ (A). Patient HIV env expression vectors are co-transfected
with an env-deleted ‘‘HIV genomic vector’’ (B) containing a firefly
luciferase reporter gene that is used to quantify viral infectivity.
Co-transfection of HIV env expression vectors and HIV genomic
vectors produces HIV-1 pseudoviruses (C) expressing the env
proteins derived from patient virus env sequences. Coreceptor
tropism is determined by measuring the ability of pseudovirus
populations to efficiently infect target cells co-expressing CD4 and
either CXCR4 (D) or CCR5 (E) co-receptors. Co-receptor
mediated infectivity is quantified by measuring luciferase infectiv-
ity in the CD4/CCR5 and CD4/CXCR4 target cells (portrayed
as yellow asterisks). In the depicted example, both CXCR4+ and
CCR5+ cells are infected by pseudoviruses using patient env and,
therefore, viral tropism would be classified as ‘‘R5/X4’’ or ‘‘dual/
mixed’’. To confirm co-receptor usage, CCR5 and CXCR4 entry
inhibitors are added to target cells (F). Viruses susceptible to
CCR5 and/or CXCR4 antagonists do not produce luciferase in
the corresponding target cells. env genes encoding envelope
proteins capable of using the CXCR4 co-receptor, the CCR5 co-
receptor, or both co-receptors are shown in green, orange and
blue, respectively.
Found at: doi:10.1371/journal.pone.0014349.s002 (0.27 MB PPT)
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